About Us
The team at HaemaLogiX, together with our collaborators, is researching unique immune-based treatments to improve outcomes in patients suffering from blood cancers. The goal of these treatments is to help a patient’s immune system fight their own disease. We aim to commercialise our therapies through a series of strategic partnerships.
HaemaLogiX was formed as a private Australian biotech company in late 2014. Soon after, we acquired the core proprietary technologies that are the foci of our research and development efforts to treat multiple myeloma. Multiple myeloma is a haematological (blood) cancer of plasma cells (B cells) that can cause focused damage to a patient’s bone marrow. Multiple Myeloma is considered treatable but generally incurable.
Since inception, our research and development activities have been funded by a small group of largely Australian investors, together with the four directors who jointly own a majority share.
The HaemaLogiX team has a wide range and depth of experience in antibody research, nonclinical & clinical development, manufacturing and commercialisation. Our Scientific Advisory Board (SAB) members are internationally recognised experts in monoclonal antibodies and haematology. Our current research and clinical trial partners are global leaders in Multiple Myeloma and AL Amyloidosis therapy.
Management Team
Damian Clarke-Bruce
Managing Director |
Chief Executive Officer
Dr. Rosanne Dunn
Director |
Chief Scientific Officer
Prof. Mohamad Hussein
Chief Medical Advisor
Dimitra Korkidas
Company Secretary |
Chief Financial Officer
Tertia Dex
Chief Manufacturing &
Development Officer
Halley Hilton
Senior Project Manager |
Clinical Research & Development
Scientific Advisory Board
Rhonda Oshanek
Senior Medical Writer
Professor
Paul Richardson
Professor
Andrew Spencer
Board of Directors
Professor
Simon Harrison
Professor
David Gottlieb
Bryce Carmine
Non-Executive Director
Alan Liddle
Non-Executive Officer
Dr. John Cullity
Chairman
Damian Clarke-Bruce
Managing Director |
Chief Executive Officer
Dr. Rosanne Dunn
Director |
Chief Scientific Officer
_edited.png)
Angela
Dispenzieri, M.D.
Professor
Jesus San-Miguel
Dr. Laurence Turka
Non-Executive Director